For virologically suppressed adult patients with HIV-1. See Full Indication.
JULUCA | Adverse Reactions
Adverse Reactions and Rates of Discontinuation Due to Adverse Events Through Week 1481,2*
*SWORD 1 & 2 (pooled data).
†Of the people who took JULUCA from Week 1 and left the study due to adverse events, the most common type of adverse event leading to discontinuation was psychiatric disorders (3%).
AEs=adverse events.
References:
- van Wyk J, Orkin C, Rubio R, et al. Durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;85:325-330. doi: 10.1097/QAI.0000000000002449
- Data on file, ViiV Healthcare.
For virologically suppressed adult patients with HIV-1
Adverse Reactions and Rates of Discontinuation Due to Adverse Events Through Week 1481*
- AEs leading to discontinuation were cumulative, 8% through Week 148 (4% from Day 1- Week 48 and 7% from Week 48-Week 100)1
- Low rates of Grade 2 to 4 drug-related AEs and serious AEs were reported1
- The majority of AEs were Grade 1 or 2
- There were 4 drug-related SAEs; all started before Week 48
- Safety profile of the late-switch group through Week 148 was comparable to the early-switch group at Week 1001
*Most common AEs leading to discontinuation were psychiatric disorders; 3% of patients who continued on JULUCA through Week 148 and 1% of patients who switched to JULUCA at Week 52.
AE = adverse event; SAE = serious adverse event
Reference:
- van Wyk J, Orkin C, Rubio R, et al. Durable suppression and low rate of virologic failures 3 years after switch to DTG+RPV 2-drug regimen: SWORD 1 & 2 studies. Presented at: 25th Annual Conference of the British HIV Association; April 2-5, 2019; Bournemouth, UK. Poster P008.
You may also be interested in
EFFICACY & RESISTANCE PROFILE

PATIENT-REPORTED OUTCOMES

LIPID AND FRACTURE DATA AND A DEXA SUBSTUDY
